In contrast to peptides and unmodified proteins, T-activated® proteins are processed and cross-presented via both the exogenous and endogenous pathway by functional antigen-presenting cells, thus mimicking a natural infection very closely. In addition, T-activated® proteins allow a more efficient and HLA antigen-independent stimulation of a broad spectrum of clinically-relevant subpopulations of immune effector cells including mature T helper cells, cytotoxic T cells, natural killer (NK) and NKT-like cells.

T-activation process exemplified by Lophius’ T-Track® CMV process

The T-activation technology has been successfully deployed and shown its potential in the T-Track® CMV diagnostic kit. Potential future diagnostic applications of the T-activation approach include supplementary diagnostic solutions for other pathogens in transplantation medicine such as Epstein-Barr virus, Adenovirus, Human Polyomavirus 1 or Aspergillus. Another opportunity to leverage the potential of the technology are specialty diagnostics, like for Lyme disease or to guide cancer immunotherapy.

This function requires IE9 or higher.
You can update your browser under: